Revance Therapeutics — Technical Presentation (December 2017)
28 slides from Revance Therapeutics's technical presentation, Dec 5, 2017
Slide 1: Topline Results: SAKURA 1 and 2 Phase 3 Pivotal Studies
Topline Results 5 December 2017 SAKURA 1 and 2 Phase 3 Pivotal Studies DaxibotulinumtoxinA for Injection (RT002) for the Treatment of Moderate to Severe Glabellar Lines Exhibit 99.2
Slide 2: Met Primary and All Secondary Endpoints
Met Primary and All Secondary Endpoints Highly statistically significant results achieved on 2-point composite primary endpoint at Week 4 Highly statistically significant reduction in severity of glabellar lines observed at Week 24 Median duration for time to return to baseline wrinkle severity on b
Slide 3: Two Pivotal Phase 3 Studies Identical in Design
Two Pivotal Phase 3 Studies Identical in Design Study Objective: To evaluate the efficacy and safety of a single treatment of DaxibotulinumtoxinA for Injection (Daxi) 40U for the treatment of moderate to severe glabellar lines compared to placebo Primary Endpoint*: Proportion of subjects achieving a
Slide 4: Study Designs
SAKURA 1 and 2 Study Designs Evaluating Subjects over 36 weeks across 30 Sites in US and Canada N=303 2:1 Randomization Week 0 1 2 4 24 36 Primary Endpoint Single Administration Last Mandatory Visit †Until both IGA-FWS and PFWS return to baseline Final Visit† Visit every 4 weeks Visit every 4 weeks†
Slide 5: Frown Wrinkle Severity Scales
SAKURA 1 and 2 Frown Wrinkle Severity Scales Both investigators and subjects trained at trial initiation on a validated 4-Point Wrinkle Severity Scale to assess severity of glabellar frown lines At entry, subjects were required to have glabellar line wrinkle severity of either Moderate or Severe as
Slide 6: Subject Disposition and Analysis Populations
SAKURA 1 SAKURA 2 Placebo (n=102) Daxi 40U (n=201) Placebo (n=102) Daxi 40U (n=204) Subject Disposition Completed Week 4 97 (95.1%) 196 (97.5%) 99 (97.1%) 203 (99.5%) Completed Week 24 91 (89.2%) 188 (93.5%) 93 (91.2%) 199 (97.5%) Completed the Study 93 (91.2%) 182 (90.5%) 93 (91.2%) 191 (93.6%) Ana
Slide 7: Demographics
SAKURA 1 and 2 Demographics SAKURA 1 SAKURA 2 Placebo (n=102) Daxi 40U (n=201) Placebo (n=102) Daxi 40U (n=204) Female, n (%) 88 (86.3%) 174 (86.6%) 87 (85.3%) 183 (89.7%) Age (years), mean (SD) range 49.0 (11.13) 22, 74 50.9 (11.22) 23, 74 50.5 ( 9.98) 27, 75 49.6 ( 9.84) 21, 73 Race White 81 (79.4
Slide 8: Baseline Characteristics
SAKURA 1 and 2 Baseline Characteristics SAKURA 1 SAKURA 2 Placebo (n=102) Daxi 40U (n=201) Placebo (n=102) Daxi 40U (n=204) Prior BoNT-A*, n (%) 45 (44.1%) 92 (45.8%) 60 (58.8%) 121 (59.3%) Months since last BoNT-A* mean (SD) range 22.6 ( 19.61) 1, 94 32.2 ( 37.05) 7, 205 23.0 ( 24.36) 7, 121 22.7 (
Slide 9: Primary Endpoint at Week 4
SAKURA 1 and 2 Primary Endpoint at Week 4 Proportion of Subjects Who Achieve > 2-Point Composite Response at Max Frown Two-Point Composite Response of 74% Achieved in Both Pivotal Phase 3 Studies %* %* % *p < 0.0001 (vs Placebo) *p < 0.0001 (vs Placebo)
Slide 10: Secondary Endpoint: None or Mild Response Rate Over Time
SAKURA 1 and 2 Secondary Endpoint None or Mild Response Rate on IGA-FWS and PFWS over Time Week SAKURA 1 SAKURA 2 Daxi 40U (n=201) Placebo (n=102) Daxi 40U (n=204) Placebo (n=102) 2 93.5%* 3.9% 98.0%* 2.0% 4 97.5%* 4.9% 97.5%* 3.9% 8 91.5%* 7.8% 94.6%* 2.9% 12 84.1%* 2.9% 88.2%* 2.9% 16 71.1%* 5.9%
Slide 11: Secondary Endpoint: Time to Loss of None or Mild Wrinkle Severity
SAKURA 1 and 2 Secondary Endpoint Time to Loss of None or Mild Wrinkle Severity on Both IGA-FWS and PFWS Median Duration of 24 Weeks Achieved for Time to Loss of None or Mild Wrinkle Severity in Both Pivotal Studies
Slide 12: Secondary Endpoint: Time to Return to Baseline
SAKURA 1 and 2 Secondary Endpoint Time to Return to Baseline on Both IGA-FWS and PFWS Median Duration of at Least 26 Weeks Observed for Time to Return to Baseline Wrinkle Severity in Both Pivotal Studies
Slide 13: Exploratory Endpoint: Median Duration of ≥1-Point Improvement on IGA-FWS
SAKURA 1 and 2 Exploratory Endpoint Median Duration of ≥ 1 Point Improvement from Baseline on IGA-FWS Median Duration of 24.1 Weeks Achieved for ≥ 1-Point Improvement in SAKURA 1 and 2 Confirmed Duration of Effect Observed in Phase 2 BELMONT Study
Slide 14: Exploratory Endpoint: Median Duration on IGA-FWS and PFWS
SAKURA 1 and 2 Exploratory Endpoint Median Duration of ≥ 1 Point Improvement from Baseline on IGA-FWS and PFWS Median Duration of 24 Weeks Achieved for ≥ 1-Point Improvement on IGA-FWS Confirmed on PFWS in Both Pivotal Studies
Slide 15: SAKURA and BELMONT Phase 2 Study Results
SAKURA 1 and 2 and BELMONT1 Phase 2 Study Results None or Mild Response on IGA-FWS over Time Week SAKURA 1 SAKURA 2 BELMONT1 BELMONT1 Daxi 40U (n=201) Daxi 40U (n=204) Daxi 40U (n=39) Onabot2 20U (n=42) 2 93.5%* 98.0%* 97.3%** 95.2%** 4 97.5%* 97.5%* 97.4%** 92.9%** 8 91.5%* 94.6%* 97.4%** 83.3%** 1
Slide 16: SAKURA Results and Botox Cosmetic and Dysport USPI Data
30 60 90 120 150 Weeks Days SAKURA 1 and 2 Results and Botox Cosmetic and Dysport USPI1 Data None or Mild Response Rates on 4-Point Investigator Assessment over Time 1United States Prescribing InformationPhase 3 Studies in GL for each neuromodulator with data available through at least Day 120 condu
Slide 17: Example Three-Point Improvement and Sustained Duration of Effect
Baseline Scores: IGA-FWS: 3 PFWS: 3 DaxibotulinumtoxinA 40U MAXIMUM FROWN Week 4 Week 24 Week 4 Scores: IGA-FWS: 0 PFWS: 0 Week 24 Scores: IGA-FWS: 0 PFWS: 1 SAKURA 1 and 2 Pre-treatment Three Point Improvement from Baseline on Investigator and Subject Assessment Three Point Improvement from Baselin
Slide 18: Patient Global Satisfaction with Treatment at Week 4
SAKURA 1 and 2 Patient Global Satisfaction with Treatment at Week 4 SAKURA 1 SAKURA 2 Very dissatisfied Dissatisfied Somewhat dissatisfied Neither satisfied nor dissatisfied Somewhat satisfied Satisfied Very satisfied Subject Ratings of ‘Very Satisfied’ or ‘Satisfied’ were 88% in SAKURA 1 and 91% in
Slide 19: Summary of Adverse Events
SAKURA 1 and 2 Summary of Adverse Events SAKURA 1 SAKURA 2 Placebo (n=102) Daxi 40U (n=201) Placebo (n=101) Daxi 40U (n=205)† Death 0 0 0 0 Serious AEs (SAE)* 1 (1.0%) 2 (1.0%) 1 (1.0%) 2 (1.0%) Subjects with any AE 25 (24.5%) 72 (35.8%) 24 (23.8%) 94 (45.9%) Severe* 1 (1.0%) 4 (2.0%) 1 (1.0%) 2 (1.
Slide 20: Treatment-Related Adverse Events by Preferred Term
SAKURA 1 and 2 Number of Treatment-Related Adverse Events by Preferred Term (≥2 % in Any Arm) Preferred Term SAKURA 1 SAKURA 2 Placebo (n=102) Daxi 40U (n=201) Placebo (n=101) Daxi 40U (n=205)** Headache 3 (2.9%) 14 (7.0%) 1 (1.0%) 12 (5.9%) Injection site pain 4 (3.9%) 10 (5.0%) 4 (4.0%) 5 (2.4%) E
Slide 21: Serious Adverse Events by Preferred Term
SAKURA 1 and 2 Serious Adverse Events by Preferred Term* Preferred Term SAKURA 1 SAKURA 2 Placebo (n=102) Daxi 40U (n=201) Placebo (n=101) Daxi 40U (n=205)† Bone marrow failure 0 1 (0.5%) 0 0 Sepsis 0 1 (0.5%) 0 0 Anxiety 1 (1.0%) 0 0 0 Uterine perforation 0 0 0 1 (0.5%) Leiomyosarcoma recurrent 0 0
Slide 22: Efficacy Summary
SAKURA 1 and 2 Efficacy Summary Both SAKURA 1 and 2 Phase 3 studies with DaxibotulinumtoxinA for Injection 40U met their primary endpoint and demonstrated duration of effect ≥ 24 weeks Primary Endpoint met 2-point composite response at Week 4 of 74% with Daxi in both studies vs. 0% and 1% with place
Slide 23: Duration of Effect Summary
SAKURA 1 and 2 Duration of Effect Summary 1Carruthers, J., et al. Injectable DaxibotulinumtoxinA for the Treatment of Glabellar Lines: A Phase 2, Randomized, Dose-Ranging, Double-Blind, Multicenter Comparison with OnabotulinumtoxinA and Placebo. Dermatol. Surg. 2017; 43: 1321 – 1331. SAKURA 1 and SA
Slide 24: Studies Safety Summary
SAKURA 1 and 2 Studies Safety Summary DaxibotulinumtoxinA 40U was observed to be generally safe and well-tolerated through Week 36 in both pivotal studies Percentage of subjects in SAKURA 1 and 2 with adverse events in the Daxi group were 36% and 46%, respectively, and 25% and 24% in the placebo gro
Slide 25: Botulinum Toxin Market Showing Continued Global Growth
Botulinum Toxin Market Showing Continued Global Growth Compound Growth Rate of 10.7% Across Geographies Source: Global Industry Analysts, Inc. – Botulinum Toxin – A Strategic Business Report – Sept. 2016
Slide 26: Duration is the #1 Aesthetic Physician Unmet Need
Duration is the #1 Aesthetic Physician Unmet Need Long-lasting is the #1 Patient Request RT002 has the potential to be the first neuromodulator to deliver on the most important physician unmet need and patient request
Slide 27: Building Momentum for Commercial Success
Building Momentum for Commercial Success BRANDING AND MARKET LAUNCH PREPARATIONS UNDERWAY NURTURING RELATIONSHIPS & FOSTERING ADVOCACY ASSEMBLING COMMERCIAL OPERATION To Drive MARKET ADOPTION REVANCE PRODUCT VELOCITY LAUNCH PLAN
Slide 28: Met Primary and All Secondary Endpoints
Met Primary and All Secondary Endpoints Highly statistically significant results achieved on 2-point composite primary endpoint at Week 4 Highly statistically significant reduction in severity of glabellar lines observed at Week 24 Median duration for time to return to baseline wrinkle severity on b
Revance Therapeutics — Technical Presentation (December 2017) on 6ix